Nasolabial fold filler: what an assessment should establish

Before choosing a nasolabial fold filler, establish what you want the treatment to change. A softer crease at rest is a different goal from expecting no fold when you smile. The useful question is not simply which brand to use, but whether the proposed treatment addresses your concern, what it may leave unchanged and what risks you would be accepting.

Define the concern before choosing the product

Nasolabial folds are the nose-to-mouth folds. Marionette lines extend downward from the mouth corners toward the chin; a jawline concern involves a different contour. These location descriptions help you explain what bothers you, but they are not a photograph-based test for selecting an injection. Cleveland Clinic's explanation of marionette lines distinguishes the two areas.

Try turning a broad request such as “remove my lines” into a specific question: are you concerned about the crease itself, the shadow beside the mouth, or the way the area looks during expression? Ask the clinician to explain which aspect the proposed treatment is intended to change. A visible fold should not automatically be treated as a simple shortage of volume.

What a filler study can—and cannot—tell you

Two studies in the original U.S. regulatory dossier for Restylane Refyne and Restylane Defyne illustrate an important distinction. Each was a separate randomized, evaluator-blinded study: participants received the study filler on one side of the face and a hyaluronic acid control filler on the other. Refyne and Defyne were not tested against each other.

Participants had moderate or severe folds. The main assessment was 24 weeks after the final initial injection: either the first treatment or the optional initial touch-up, if one was performed. Follow-up visits continued through week 48.

The Wrinkle Severity Rating Scale, or WSRS, graded folds on five levels. The noninferiority test assessed whether the reduction in severity was no worse than the control by more than the prespecified margin; it did not establish a universal “best filler.” A lower score does not mean the fold disappeared, and an assessment at 24 weeks does not mean everyone needs another injection then. The FDA study record lets you examine the findings for those particular products and participants.

Bring the history that changes the conversation

An assessment should connect your goals with an examination and relevant medical history. Mention previous fillers, implants and other cosmetic procedures, including past reactions. Bring product names and treatment dates if you have them. Discuss allergies, health conditions, medicines and supplements; the American Academy of Dermatology's preparation guidance identifies these as information to share before filler treatment.

Then ask for a description of the intended result in ordinary language. “Which part of the fold might soften?” is more useful than accepting a product name as the entire explanation. Ask what may remain visible at rest and during expression, and how improvement will be assessed afterward.

Questions a treatment proposal should answer

These are questions for a discussion, not an injection plan:

• Why is this area being targeted for the change I want?
• What can the proposed approach reasonably leave unresolved?
• What alternatives should I consider, including having no procedure?
• What follow-up is planned, and how would an unexpected problem be assessed?

If treatment elsewhere in the face is proposed, ask why that approach fits your concern. An individual plan needs an explanation beyond a brand comparison.

Know which symptoms need urgent attention

The product information lists reactions such as swelling, bruising, redness and tenderness. It also warns that filler entering a blood vessel can cause serious injury, including skin damage and vision loss. Unusual pain, a patch of skin turning pale or visual changes during or soon after injection need immediate medical attention. Visual or neurological symptoms are an emergency, not something to leave until a routine follow-up.

Injection should be deferred where there is active infection or inflammation until it is controlled. Contraindications and precautions must be checked for the exact product; having tolerated another filler does not replace that assessment. See the U.S. instructions for Refyne and Defyne.

Further reading

For the broader material categories and safety discussion, read the guide to facial fillers. For questions about product distinctions, see hyaluronic acid filler brands. Those topics provide context; neither replaces an assessment of the particular area you want to discuss.